LDL cholesterol targets depend on cardiovascular risk, guidelines say

European cardiology guidelines retained risk-based low-density lipoprotein cholesterol (LDL-C) targets in 2025, ranging from below 116 mg/dL for adults at low cardiovascular risk to below 55 mg/dL for those at very high risk. The figures are treatment goals within a European framework, not universal laboratory reference ranges.

The European Society of Cardiology (ESC) said its 2025 focused update retained the LDL-C goals and risk categories from its 2019 joint guideline with the European Atherosclerosis Society. The target that applies to an adult depends on cardiovascular history, other medical conditions, baseline LDL-C and an assessment of future risk.

Heart attack and stroke signs require immediate care

An LDL-C result describes longer-term risk and cannot assess an emergency. The World Health Organization says chest pain or discomfort, pain extending to the arms, shoulder, jaw or back, shortness of breath, faintness or a cold sweat can signal a heart attack; sudden one-sided weakness, speech or vision trouble, loss of balance or a severe unexplained headache can signal a stroke. Anyone with these symptoms needs immediate medical care through the local emergency service.

A laboratory reference range is not a personal treatment goal

A lipid panel commonly reports total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides. A laboratory may flag a result against its reference interval, but a treatment goal answers a different question: how far LDL-C should be lowered for a person with a defined level of cardiovascular risk.

A result that is not flagged can therefore sit above a guideline target for someone with established atherosclerotic cardiovascular disease or another high-risk condition. The reverse distinction also matters: one test outside a laboratory interval does not by itself select a medicine or establish a diagnosis. A clinician may review repeat results, blood pressure, smoking, diabetes, kidney function, family history and previous heart or blood-vessel disease before setting a target.

European targets become lower as risk rises

The 2019 ESC and European Atherosclerosis Society guideline sets adult LDL-C goals below 3.0 mmol/L (116 mg/dL) at low risk and below 2.6 mmol/L (100 mg/dL) at moderate risk. At high risk, the goal is below 1.8 mmol/L (70 mg/dL) with at least a 50 percent reduction from baseline. At very high risk, it is below 1.4 mmol/L (55 mg/dL) with at least a 50 percent reduction.

The 2025 update changed parts of European risk estimation but kept those treatment goals. Its SCORE2 and SCORE2-Older Persons tools estimate 10-year fatal and nonfatal cardiovascular risk in apparently healthy adults across age bands and are calibrated to cardiovascular mortality in European countries. They are not designed to reassess people with established atherosclerotic disease or those already taking lipid-lowering treatment.

Country and clinical history change the interpretation

The European categories should not be copied into a universal self-assessment. National guidelines can use different calculators, thresholds and screening schedules. Diabetes, chronic kidney disease, familial lipid disorders and previous cardiovascular events may also place a person outside the risk-calculator pathway used for an otherwise healthy adult.

Children and adolescents need age-specific assessment rather than the adult table. Pregnant or breastfeeding people, older adults with frailty, people with liver or kidney disease and anyone taking regular medicines should discuss a lipid result and any proposed treatment or supplement with a clinician. Treatment availability and regulatory status vary by country.

Treatment intensity follows risk, not one abnormal number

The WHO identifies tobacco use, an unhealthy diet, physical inactivity and harmful alcohol use among major modifiable cardiovascular risk factors. Addressing those factors remains part of prevention, but lifestyle changes and prescribed lipid-lowering treatment are not interchangeable for every risk group.

The 2025 ESC update recommends statins as the first drug choice and recommends non-statin therapy with proven cardiovascular benefit when the maximum tolerated statin does not reach the LDL-C goal or cannot be used. The selection and timing of prescription treatment require a clinician's judgment. Regulatory approval, reimbursement and availability differ among countries.

Red yeast rice is not a risk-free substitute

Red yeast rice supplements can contain monacolin K, a compound chemically identical to the cholesterol-lowering medicine lovastatin. Product composition is not standardized, and a label or the word “natural” does not establish that a supplement has the same evidence, dose control or monitoring as a prescribed medicine.

The European Food Safety Authority (EFSA) concluded in 2025 that submitted data did not establish the safety of red yeast rice monacolins below 3 mg a day or identify an intake without safety concerns for the general population or vulnerable groups. EFSA said reports at 3 mg a day included severe muscle injury, including rhabdomyolysis, and liver effects. The assessment concerned safety and did not evaluate whether potential benefits outweighed those risks.

European Union rules require red yeast rice supplements to contain less than 3 mg of monacolins in a recommended daily portion and to warn against use with cholesterol-lowering medication, during pregnancy or breastfeeding, and by children. That restriction is not a finding that amounts below 3 mg are safe; EFSA's later review could not establish such a level. Rules and product availability outside the European Union may differ.

The ESC's 2025 update does not recommend dietary supplements or vitamins to lower LDL-C and reduce atherosclerotic cardiovascular risk. Someone already taking a cholesterol-lowering medicine should not add red yeast rice or replace prescribed treatment without clinical review.

How to read the result without overreading it

Record whether the sample was fasting if the laboratory requested it, keep the units and compare results from the same laboratory where practical. Bring the full panel and a current medicine and supplement list to the appointment. The useful question is not only whether LDL-C falls inside a printed interval, but which guideline and risk category apply.

APPI News could not verify one worldwide adult screening schedule or one LDL-C target framework used in every market. The European figures in this guide show why a single “normal” cutoff can mislead, but a clinician should use guidance adopted for the reader's country and circumstances.

Frequently asked questions

Is LDL-C below 130 mg/dL normal for everyone?
No. A laboratory reference interval is not the same as a treatment goal. In the European framework, adult targets range from below 116 mg/dL at low risk to below 55 mg/dL at very high risk, and national guidance can differ.

Who uses the 70 mg/dL and 55 mg/dL goals?
The ESC/EAS guideline assigns below 70 mg/dL plus at least a 50 percent reduction to high-risk adults and below 55 mg/dL plus at least a 50 percent reduction to very-high-risk adults. A clinician determines the category from medical history and a validated risk assessment.

Can diet and exercise replace cholesterol medicine?
They are part of cardiovascular prevention, but they do not replace prescribed treatment for every person. The 2025 European guidance uses overall risk and the LDL-C reduction required to decide how intensive treatment should be.

Can red yeast rice replace a statin?
The European guideline does not recommend supplements to lower LDL-C and cardiovascular risk. EFSA also could not establish a safe intake of red yeast rice monacolins, and European Union labels warn against combining them with cholesterol-lowering medication.

How often should cholesterol be checked?
There is no single schedule verified for every country. Age, previous results, cardiovascular history, treatment and national screening policy affect the interval.